Falbikitug is a humanized IgG1 monoclonal antibody targeting leukemia inhibitory factor (LIF). it inhibits downstream signaling by specifically blocking the recruitment of the glycoprotein 130 (gp130) coreceptor to the LIF receptor (LIFR) subunit (gp190), consequently preventing the phosphorylation of signal transducer and activator of transcription 3 (STAT3), and is intended for treating advanced solid tumors.